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The prevalence of AF is highly age-dependent, ranging from 0.1% in those aged <55 years to 9% in those aged ≥80 years. 3 With greater life-expectancy, the absolute number of individuals with AF is anticipated to increase substantially in the coming decades, even if current incidence rates remain unchanged. However, data indicate that AF incidence is increasing, leading to projections of an increase in AF prevalence in the United States by at least 2.5-fold by 2050. 3, 4 The consequences of this increase in AF prevalence on the frequency of AF-related stroke will depend on the effectiveness of AF detection and implementation of prevention with anticoagulants and other vascular medications and behaviors.
As health costs rise and health budgets become constrained in many developed countries, cost of illness studies are becoming increasingly important to understand the financial burden of chronic diseases to society, to identify modifiable cost drivers, and to inform rational decisions relating to reimbursement strategies for preventive medications, hospital treatments, and community care. In addition to being a leading cause of global death, disability, and dementia, stroke is an expensive disease, costing an estimated $34 billion annually in the United States alone. 5 Cost-of-illness studies have described substantially higher hospital costs of AF-stroke compared with other stroke mechanisms, associated with greater stroke severity and longer hospital stays. 6, 7 However, most studies were limited by inclusion of selected, hospital-admitted patients, which may have led to bias and underestimation of true costs. No studies to date have estimated population-based projections for the future burden of AF-stroke measured in terms of the total numbers affected, and the accompanying cost implications at a state-wide or national level.
In this issue of Circulation, Yiin and colleagues 8 describe a comprehensive analysis of the incidence, event rates, outcomes, and costs of ischemic stroke and systemic embolism associated with AF in the population-based Oxford Vascular Study (OXVASC) from 2002 to 2012 compared with the earlier Oxford Community Stroke Project (OCSP), conducted from 1981 to 1986 in the same region. Their main findings are a 3-fold increase in the numbers of AF-strokes in patients aged ≥80 years, partly related to increased incidence in older individuals. After adjusting for age and sex, the incidence of AF-stroke in those aged >80 years increased 1.5-fold, but was unchanged in those aged <80 years (P for interaction 0.014).
Although oral anticoagulation use had increased in OXVASC compared with OCSP (12.3% versus 3.5%), no improvement was seen in OXVASC when 2002 through 2007 was compared with 2007 through 2012. In patients with known AF, only 16.7% were treated with warfarin before stroke onset and the international normalized ratio was subtherapeutic in 60% of these at stroke onset. Oral anticoagulation was particularly underused in high-risk individuals defined by CHADS2/ CHADS2VA2SC scores.
Projected rates for AF-stroke by 2050 were estimated assuming a neutral scenario of no change in current incidence rates, and a worst-case scenario of continuing increase in AF-stroke incidence based on the observed change between OCSP and OXVASC. Under the neutral constant-incidence scenario, the number of UK individuals with AF-embolic events was projected to increase 2.5-fold, from 35 000 to 87 000, 84% occurring in those aged >80 years. Under the worst-case scenario, 156 000 strokes and systemic embolic events were projected, a 4.5-fold increase.
Observed average per-patient hospital costs for AF-stroke were similar regardless of age, but costs of long-term institutional care were doubled in those aged >80 years. Under their constant-incidence scenario, annual UK costs were estimated at almost £2 billion by 2050, ≈70% of which was incurred by those aged >80 years.
How are these results to be interpreted by clinicians and policy-makers within and outside the United Kingdom? First, in contrast to earlier studies of selected hospital patients, the OXVASC group used robust and rigorous methodology to minimize the possibility of selection bias, including the population-based design and overlapping ascertainment methods. 9, 10 Other strengths include prospective and prolonged
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follow-up of study participants, inclusion of posthospital community costs, and inclusion of systemic embolic events. Their crude incidence rates of AF-stroke (41/100 000 personyears) are similar to other recent population studies in Dublin and Dijon, 1, 11 which strengthens the validity of their findings. Similar methods for ascertainment of stroke and AF were used in OCSP and OXVASC, which reduces the likelihood that their findings relate to improved ascertainment over time. Ambulatory cardiac monitoring for paroxysmal AF was not routinely performed in either study, which may have led to underdetection of some patients with AF, but this is unlikely to have differed between the 2 studies.
Second, the degree to which their findings may be generalized beyond the Oxfordshire population should be considered. Stroke incidence rates are influenced by socioeconomic profile, health behaviors, and use of vascular preventive therapies in the underlying population. The degree to which their population sample is representative of other populations or healthcare systems is unclear, as the authors rightly acknowledge. In contrast to the Oxford findings, other long-term population studies in the United States and France have observed reductions of 1.5% to 3% annually in AF-stroke incidence between the 1980s and 2000s, associated with substantial increases in the use of oral anticoagulation and other preventive therapies, despite the increasing age profile of their underlying populations.
11,12
The Oxford study is a timely warning call alerting clinicians, health advocates, and policy-makers of the flood of costly AF-related strokes and embolic events that may be expected if preventive action is not taken. The findings of other studies provide grounds for optimism that increases in AF-stroke are not inevitable if effective steps are taken to detect AF, assess stroke and bleeding risk, and begin appropriate prevention. 13, 14 To ensure that these actions are effective and equitable at population level, states and health systems should develop and implement comprehensive AF policies, supported by adequate funding.
Disclosures
Dr Kelly is supported by grant funding from the Health Research Board of Ireland and Irish Heart Foundation. He has received honoraria for contributions to advisory boards or conferences supported by Bayer, Pfizer, Bristol Myers Squibb, Boehringer-Ingelheim, and Daiichi Sankyo.
